NCT03236428 · OUTCOME

Complete Response Rate

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma · Source last updated 2026-03-27

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 2 years

What was measured

The duration of overall CR is progression or death. Patients who have not progressed or died are censored at the date last known progression-free.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: The duration of overall CR is progression or death. Patients who have not progressed or died are censored at the date last known progression-free.
reporting Status: NOT_POSTED
time Frame: 2 years
title: Complete Response Rate
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice